Client : Novartis Japan
Opportunity: With the proven clinical success in the late 90’s of octreotide, the active ingredient in Sandostatin and Sandostatin LAR used in the long-term maintenance therapy in patients with acromegaly and in the treatment of symptoms related to carcinoid syndrome, Novartis Japan started production and distribution in Japan. The current packaging was redesigned for the Japanese market.
Solution: Developed a clean design with impact using a unifying red color for the product name and a refreshing color palette for background differentiation.
Responsibilities: Creative Direction, Design and Production Coordination.